Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Clinches Immuno-Oncology Drug Discovery Deal with Numab
March 29, 2017
- AZ Japan to Introduce Business Unit Structure in April
March 28, 2017
- Tivantinib Fails Japan PIII Trial for HCC: Kyowa Kirin
March 28, 2017
- Nippon Shinyaku Gets Exclusive Japan Rights to Novel AML Drug
March 27, 2017
- Chugai Notches Supreme Court Victory in Oxarol Patent Suit
March 27, 2017
- AZ Gets Asian Rights to Kyowa Kirin’s Benralizumab
March 27, 2017
- Nobelpharma to Copromote Nobelzin with ASKA, Medipal upon Hypozincemia Nod
March 27, 2017
- EMA Accepts Schizophrenia Med Brexpiprazole for Review: Otsuka/Lundbeck
March 27, 2017
- Torii Seeks Pediatric Indication for Allergen Immunotherapy Miticure
March 27, 2017
- Shionogi Gets FDA Nod for Naldemedine
March 27, 2017
- Hit Compounds Enter POC Evaluation Stage in DNDi’s NTD Drug Discovery Booster Project
March 27, 2017
- Alexion Files Soliris for Refractory gMG
March 24, 2017
- Takata, Meiji Settle Patent Suit with Toyama Chemical over Pediatric Ozex Drug
March 24, 2017
- Wholesale Dealer President Deeply Sorry for Letting Fake Harvoni into Supply Chain
March 24, 2017
- Koshiya Tapped as Global Head of Oncology: Sumitomo Dainippon
March 23, 2017
- Japan Begins Using PD-L1 Expression Biomarker for Immune Checkpoint Inhibitors, but Challenges Linger
March 22, 2017
- US Biotech X-Chem Inks Collaboration Deals with Astellas, Ono
March 22, 2017
- Praluent Shows Consistent Efficacy, Safety in Diabetic and Non-Diabetic Patients: Japanese Subanalysis
March 22, 2017
- Ribomic Links Up with Astellas for Research on Development of Aptamer Therapy
March 22, 2017
- Hitachi Chemical to Buy US Cell Therapy Contract Manufacturer, Japan-Bound Operations Slated for FY2018
March 21, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…